

Disclosures

Personal Commercial (3)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|-------------------------|---------------------------|--------------------------|------------------------------------|
| <i>Self</i> | | | |
| Alnylam Pharmaceuticals | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Pfizer | Research/Research Grants | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Pfizer, Inc | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |

Additional Personal Commercial Disclosures for Education Activities (3)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|--------------|--------------------------|--------------------|--------------------|
| <i>Self</i> | | | |
| Alnylam | Research/Research Grants | Modest (< \$5,000) | General Cardiology |
| Bridge Bio | Other - Advisory Board | Modest (< \$5,000) | |
| Pfizer Inc | Research/Research Grants | Modest (< \$5,000) | General Cardiology |

Personal Organizational or Other Non-Commercial (5)

| Non-Commercial Entity Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------------------|---------------------------|--------------------------|--------------------|
| <i>Self</i> | | | |
| Akari | Research/Research Grants | Modest (< \$5,000) | General Cardiology |
| Alnylam | Research/Research Grants | Modest (< \$5,000) | General Cardiology |
| Alnylam | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| Pfizer | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |
| Pfizer | Research/Research Grants | Modest (< \$5,000) | General Cardiology |

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/1/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.